0000000000353045

AUTHOR

Arancha Bermúdez

showing 2 related works from this author

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic ha…

2021

BACKGROUND: Cytomegalovirus (CMV) is a complication of allogeneic haematopoietic cell transplantation (allo-HCT). ASP0113, a DNA-based vaccine, contains two plasmids encoding human CMV glycoprotein B and phosphoprotein 65 (pp65). We assessed ASP0113 in CMV-seropositive allo-HCT recipients. METHODS: In this phase 3, randomised, placebo-controlled study, CMV-seropositive allo-HCT recipients were randomly assigned (1:1) via interactive response technology to receive five injections of 1 mL of 5 mg/mL ASP0113 or placebo. The pharmacist and designated staff were unblinded. Masked syringes maintained the blind for patients and study personnel. Efficacy and safety analyses included patients who re…

medicine.medical_specialtyPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerDiseaseGANCICLOVIRPlacebo01 natural sciencesPROPHYLAXIS03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineMedicine General & Internal[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineGeneral & Internal MedicinemedicineCYTOMEGALOVIRUS DISEASE030212 general & internal medicine0101 mathematicsAdverse effectlcsh:R5-920Science & Technologybusiness.industryIncidence (epidemiology)010102 general mathematicsGeneral MedicineOdds ratioConfidence interval3. Good healthbusinessComplicationlcsh:Medicine (General)Life Sciences & BiomedicineResearch PaperEClinicalMedicine
researchProduct

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable res…

2021

Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH).

OncologyMalep13)/TCF3-PBX1Neoplasm ResidualOncogene Proteins FusionCytogenetic alterationsmedicine.medical_treatmentDiseaseTranslocation Genetichemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocolst(1;19)(q23;p13)/TCF3-PBX1Cumulative incidenceCitogenètica humanaNeoplasm MetastasisLeucèmia limfoblàstica - TractamentHuman cytogeneticsLeukemiaAcute lymphoblastic leukaemiaRemission InductionLeucèmiaDisease ManagementHematologyMiddle AgedPrognosisHaematopoiesismedicine.anatomical_structureTreatment OutcomeChromosomes Human Pair 1TCF3:Other subheadings::Other subheadings::/therapy [Other subheadings]FemaleStem cell:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor B-Cell Lymphoblastic Leukemia-Lymphoma [DISEASES]Adultmedicine.medical_specialtyPronòstic mèdicAdolescentQuimioteràpia combinadaYoung AdultInternal medicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAdultsHumansB cell19)(q23Neoplasm Staging:neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células B precursoras [ENFERMEDADES]business.industryacute lymphoblastic leukaemia adults cytogenetic alterations prognosis t(1:Otros calificadores::Otros calificadores::/terapia [Otros calificadores]ImmunotherapyChromosome BandingTransplantationt(1Avaluació de resultats (Assistència sanitària)businessChromosomes Human Pair 19British journal of haematologyReferences
researchProduct